Unusual volume stocks in Tuesday's session
TSCAN THERAPEUTICS INC (TCRX) 1.8 -0.02 (-1.1%)
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session.
Unusual volume stocks
| Ticker | Change | Comment |
|---|---|---|
| GNS | 1.06% | 56.73M shares of GENIUS GROUP LTD (NYSEARCA:GNS) have been traded so far today. Shares are rising by 1.06%. This is 304.0% above the average daily volume of the last 50 days. A press release (Genius Group 2023 Financial Guidance: $48m - $52m Revenue, Positive EBITDA) was released yesterday. |
| INBS | 11.79% | INTELLIGENT BIO SOLUTIONS IN's (NASDAQ:INBS) traded a high volume of 22.89M shares. Shares are rising by 11.79%. This volume is 660.0% above the average 50 day volume. |
| IDAI | -3.16% | 863.1K shares of T STAMP INC-CLASS A (NASDAQ:IDAI) exchanged hands today. NASDAQ:IDAI is declining 3.16% today. The average volume measured over 50 days is 415.48K, so this is 108.0% above the average volume. |
| OTRK | 20.57% | 5.58M shares of ONTRAK INC (NASDAQ:OTRK) exchanged hands today. NASDAQ:OTRK is advancing 20.57% today. This is 23.79% above the average daily volume of the last 50 days. |
| BTB | 4.27% | So far 3.45M shares of BIT BROTHER LTD (NASDAQ:BTB) have traded in today's session. Leading to a price increase of 4.27%. This is 65.86% above the average daily volume of the last 50 days. |
| TCRX | -3.85% | TSCAN THERAPEUTICS INC (NASDAQ:TCRX) has an unusual volume of 376.97K shares today. NASDAQ:TCRX is declining 3.85% today. The average daily volume over 50 days is 149.29K, so this is 153.0% above the average volume. A press release (TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors) was released yesterday. |
| HLBZW | -7.2% | 402.36K shares of HELBIZ INC-CW24 (NASDAQ:HLBZW) exchanged hands today. Leading to a price decrease of 7.2%. The average daily volume over 50 days is 101.93K, so this is 295.0% above the average volume. |
| AZ | -12.15% | 192.1K shares of A2Z SMART TECHNOLOGIES CORP (NASDAQ:AZ) exchanged hands today. The share price decreased by 12.15%. The average daily volume over 50 days is 127.08K, so this is 51.17% above the average volume. |
| FAZE | -5.75% | FAZE HOLDINGS INC (NASDAQ:FAZE) has an unusual volume of 658.35K shares. NASDAQ:FAZE is declining 5.75% today. The average volume measured over 50 days is 258.52K, so this is 155.0% above the average volume. |
| VERB | -47.63% | 36.71M shares of VERB TECHNOLOGY CO INC (NASDAQ:VERB) have been traded so far today. NASDAQ:VERB is declining 47.63% today. This is 657.0% above the average daily volume of the last 50 days. |
Our unusual volume stocks screener will show you the full list.
TCRX Links
TCRX News
8 days ago - ChartmillUnusual volume stocks in Tuesday's sessionLet's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session.
8 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning!
9 days ago - ChartmillWhich stocks are moving after the closing bell on Monday?Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
9 days ago - Seeking AlphaTScan stock rises ~15% on FDA nod to start trials of cancer drugsTScan Therapeutics (TCRX) said that the U.S. Food and Drug Administration ((FDA)) cleared its investigational new drug ((IND)) applications seeking to start trials of cancer drugs...
9 days ago - TScan Therapeutics, Inc.TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid TumorsPrimary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies based on...
a month ago - TScan Therapeutics, Inc.TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent ProgressPhase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023 ...
2 months ago - TScan Therapeutics, Inc.TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022Poster presents Phase 1 trial design and translational assays to generate early evidence of biological activity in residual leukemia after hematopoietic cell transplantation
WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
2 months ago - TScan Therapeutics, Inc.TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston GlobeWALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Follow us for more
